ReviewAdvances in pharmacological and pharmaceutical sciences2025
Novel Pharmacological Approaches for Multidrug-Resistant Tuberculosis: Review.
Review in Advances in pharmacological and pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects.Archives of microbiology · 2026Review
- Novel Pharmacological Approaches for Multidrug-Resistant Tuberculosis: Review.Advances in pharmacological and pharmaceutical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Due to its resistance to common anti-TB drugs, multidrug-resistant tuberculosis (MDR-TB) presents substantial treatment problems. Optimizing therapeutic outcomes requires individualized treatment plans that take into account patient comorbidities, medication susceptibility profiles, and past treatment history. The significance of individualized medication in the treatment of MDR-TB is emphasized in this study. Methods of Review: Current research on tailored treatment plans for MDR-TB is summarized in this review. It highlights how pharmacogenomics, medication sensitivity testing, and patient-centered care can be used to customize treatment plans. The utilization of combination therapies, monitoring and adaptation techniques, and novel treatment options-such as adjuvant therapy and newer agents-are also covered in the review. Findings: Important findings show that thorough medication susceptibility testing is essential for directing wise treatment decisions. Dosage modifications based on individual metabolic responses can be informed by pharmacogenomic data. Treatment regimen adherence is improved when patients participate in decision-making. Combination therapy involving new drugs has demonstrated potential for increasing therapeutic effectiveness while reducing the emergence of resistance. Frequent monitoring makes it possible to promptly modify therapy in response to the patient response. Conclusions: Treatment for MDR-TB must be individualized and comprehensive due to its complexity. For individuals with MDR-TB, therapy outcomes can be greatly enhanced while lowering the risk of further resistance by combining host-directed therapies, pharmacological breakthroughs, and continuous patient monitoring. Enhancing customized care solutions in this difficult field of infectious illness management requires ongoing research and innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.